Global Collaboration Advances Pandemic Preparedness with New Pathogen Sharing System
Geneva – International negotiations are gaining momentum towards a landmark agreement designed to revolutionize how the world prepares for and responds to future pandemics. This week, representatives from World Health Organization (WHO) Member States made significant progress in developing the Pathogen Access and Benefit-Sharing (PABS) system, a critical component of a broader pandemic agreement currently under negotiation. The resumed session of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement, held from January 20-22, 2026, focused on refining the framework for the equitable sharing of vital resources during health emergencies.
Understanding the Pathogen Access and Benefit-Sharing System
The PABS system aims to address a fundamental challenge in global health security: ensuring rapid and equitable access to pathogens with pandemic potential and the benefits derived from their study. Currently, the sharing of biological samples and genetic information can be hampered by logistical hurdles, intellectual property concerns, and a lack of clear mechanisms for benefit-sharing. This new system seeks to overcome these obstacles by establishing a transparent and accountable framework for collaboration.
At its core, the PABS system envisions a world where countries willingly share pathogens and genetic sequence information, knowing that they will receive fair and equitable benefits in return. These benefits could include access to vaccines, therapeutics, diagnostics, and other essential medical countermeasures developed using the shared resources. The system is designed to incentivize collaboration and accelerate the development of solutions to emerging health threats.
The negotiations are particularly focused on defining the scope of “benefits” and establishing mechanisms for their distribution. Key considerations include ensuring access for low- and middle-income countries, protecting intellectual property rights, and fostering innovation. What safeguards will be put in place to prevent exploitation and ensure genuine equity in the distribution of life-saving technologies?
Established by the World Health Assembly (WHA), the IGWG is tasked with drafting and negotiating the PABS system, with a priority on enabling safe, transparent, and accountable sharing of pathogens and their genetic information. This includes the fair and equitable distribution of benefits, such as vaccines, treatments, and diagnostic tools. The current negotiations build upon an initial agreement adopted by the WHA in May 2025, and are seen as a crucial step towards strengthening global pandemic preparedness.
The resumed session followed a request by Member States to extend the fourth meeting of the IGWG, which took place in December 2025, demonstrating a strong commitment to accelerating progress on this vital initiative. Further meetings are planned in the coming months to continue the negotiations and finalize the agreement.
External resources offer further insight into the complexities of pandemic preparedness. The Council on Foreign Relations provides comprehensive analysis of global health security challenges, while the Brookings Institution offers research on pandemic prevention and response.
“I am encouraged by the progress we have made in several areas, with signs of emerging consensus for some parts of the Pathogen Access and Benefit-Sharing system,” stated Ambassador Tovar da Silva Nunes of Brazil, a co-chair of the IGWG Bureau. “As we look ahead to the fifth session, the focus will be on the outstanding, complex issues. The resumed session has helped us gain a clearer picture of where we stand.”
Mr. Matthew Harpur, of the United Kingdom and also a co-chair of the IGWG Bureau, echoed this sentiment, noting, “Member States have engaged in constructive discussions this week. As we make progress towards the May deadline, I am encouraged by their willingness to work together and bridge differences to deliver an effective Pathogen Access and Benefit-Sharing system.”
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, emphasized the importance of a robust PABS system, stating, “A strong Pathogen Access and Benefit-Sharing system will be a cornerstone of a safer and more equitable world. I thank countries for their commitment to multilateral solutions.” The outcome of the IGWG’s work will be submitted to the Seventy-ninth World Health Assembly in May 2026 for consideration.
The development of this system raises important questions about international cooperation and the balance between national interests and global health security. Will the PABS system truly level the playing field, ensuring that all countries have access to the resources they need to protect their populations during a pandemic? The coming months will be critical in determining the answer.
Frequently Asked Questions About the PABS System
-
What is the primary goal of the Pathogen Access and Benefit-Sharing (PABS) system?
The PABS system aims to facilitate the rapid and equitable sharing of pathogens with pandemic potential and the benefits derived from their study, including vaccines, therapeutics, and diagnostics.
-
Who is responsible for drafting and negotiating the PABS system?
The Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement, established by the World Health Assembly (WHA), is responsible for this task.
-
What benefits are expected to be shared through the PABS system?
Benefits include access to vaccines, therapeutics, diagnostics, and other essential medical countermeasures developed using shared pathogens and genetic information.
-
When is the expected deadline for finalizing the PABS system?
The outcome of the IGWG’s work will be submitted to the Seventy-ninth World Health Assembly in May 2026 for consideration.
-
How does the PABS system address concerns about intellectual property rights?
Negotiations are ongoing to balance the need for innovation with the imperative of equitable access to essential medical countermeasures, addressing intellectual property concerns within the framework of benefit-sharing.
Stay informed about the latest developments in global health security by visiting the World Health Organization website.
Share this article with your network to raise awareness about this critical initiative! What steps do you think are most important to ensure the PABS system is truly effective and equitable? Share your thoughts in the comments below.
Related reading
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications.
- Pink Noise Boosts Brain Waste Clearance During Sleep
- Tigers' Justin Verlander makes progress toward 1 last start (newsylist.com)
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.